Evolution of platinum resistance in high-grade serous ovarian cancer

详细信息    查看全文

• 作者：Susanna L Cooke ; PhD^a ; Dr James D Brenton ; FRCP^a ; ^{james.brenton@cancer.org.uk}
• 刊名：Lancet Oncology
• 出版年：2011
• 出版时间：November, 2011
• 年：2011
• 卷：12
• 期：12
• 页码：1169-1174
• 全文大小：1K

文摘

| Figures/TablesFigures/Tables | ReferencesReferencesding=""UTF-8""?>

Summary

High-grade serous ovarian cancers account for most ovarian-cancer mortality. Although this disease initially responds well to platinum-based chemotherapy, relapse and progression to chemotherapy resistance are frequently seen. Time to relapse after first-line therapy is a predictor of response to secondary platinum treatment: more than 12 months is associated with high chance of a secondary response, whereas relapses within 6 months generally indicate platinum resistance. In this Personal View we discuss whether patterns of response, relapse, and the development of drug resistance in high-grade serous ovarian cancers are related to distinct underlying molecular and cellular biological characteristics. In particular, we propose that rapid relapse with platinum-resistant disease is due to minor subpopulations of intrinsically resistant cancer cells at presentation.